2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Non-Biological Therapies, Pharmacology, Biological Processes, Apoptosis, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Quality Improvement, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Chronic Myeloid Malignancies, CLL, Research, Fundamental Science, Translational Research, Clinical Research, Real-World Evidence, Study Population, Human, Adult
PAPER

3867 Insights into PLCγ2 R665W-driven immune dysregulation, B-cell fitness and BTK targeted therapeutic resistance from a novel conditional B-cell mouse model

Vindhya Nawaratne, PhD, Jacob Jahn2, Alexandra Chirino3, Wasif Khan4, David Coffey5, Justin Taylor, MD6
1 University of Miami, Miami, United States
2 University of Miami, Miami, United States
3 University of Miami, Miami, United States
4 University of Miami, Miami, United States
5 University of Miami, Miami, United States
6 University of Miami, Miami, United States

Background: PLCγ2 (phospholipase C gamma 2) functions as a critical signaling molecule in immune cells, particularly B-cells, and is associated with immune dysregulation. Somatic PLCγ2 mutations are a mechanism of acquired resistance to covalent and non-covalent Bruton tyrosine kinase (BTK) inhibitors in chronic lymphocytic leukemia (CLL), yet virtually nothing is known about how these mutations alter B-cell biology in vivo independent of drug exposure. Germline PLCγ2 mutations drive immunodeficiency syndromes (PLCγ2-associated Antibody deficiency and Immune Dysregulation (PLAID) and Autoinflammatory PLCγ2-associated Antibody deficiency and Immune Dysregulation (APLAID)). In CLL, the recurrent PLCγ2 R665W is the most frequently occurring BTKi resistance mutation in 45% of cases and always occurs in a heterozygous manner. To characterize PLCγ2 function in vivo in B-cells, both in and out of a cancer context, we generated conditional B-cell specific Mb1-Cre+ PLCγ2 R665W heterozygous mice with and without crossing to the CLL mouse model Eμ-TCL1.

Methods: C57BL/6 PLCγ2 R665W mice were generated and crossed to C57BL/6 Mb1-Cre to produce B-cell restricted Mb1-Cre+ PLCγ2 R665W heterozygous mice. The point mutation was confirmed using Sanger sequencing of purified B-cells. To analyze blood cell types, beginning at week 4, and at subsequent 4-week intervals, the mice were weighed, bled, and flow cytometry was performed (n≥10, 5M and 5F). These mice were followed until end-of-life and a Kaplan-Meier survival curve was generated. To study B-cell development, B-cell subtypes were analyzed at week 12 and 48 in blood, spleen and bone marrow (n≥9). To measure immunoglobulins, serum was analyzed using enzyme-linked immunosorbent assay (ELISA) before and after immunization with trinitrophenyl keyhole limpet hemocyanin (TNP-KLH). The transcriptional landscape and immune cell repertoire were evaluated by single-cell RNA sequencing (scRNA-seq) and VDJ sequencing of splenocytes collected at week 12 (n = 5). Western blot analysis was performed on lysates from isolated B-cells to evaluate signaling pathway activation. Mb1-Cre+ PLCγ2 R665W mice were crossed to Eμ-TCL1 to study R665W in a CLL context. HBL1 and MEC1 cell lines were used to check for BTKi and BTK degrader resistance.

Results: B-cell–restricted PLCγ2 R665W expression did not affect overall survival or weight but caused a sustained reduction in total white blood cells and B-cells, with the most pronounced differences at week 12 and after week 32, suggesting a possible developmental or selection disruption. B-cell subtyping at week 12 and 48 showed decreased peripheral blood T2 transitional B-cells and decreased spleen follicular II B-cells in experimental vs control mice. There was also increased IgM in serum of experimental mice at week 12, suggesting immune dysregulation. Ongoing studies following antigenic immunization suggest altered activation potential in mutant B-cells. scRNAseq on week 12 splenocytes revealed decreased B-cell receptor signaling through ERK1/2 and NFκB in almost all mutant B-cell subtype clusters. However, there was no change in the B-cell receptor (BCR) repertoire as revealed by the VDJ sequencing.

In the CLL context, Eμ-TCL1 Mb1-Cre+ PLCγ2 R665W mice exhibited significantly reduced total B-cells and a non-significant trend toward fewer CD19+CD5+ leukemic cells, without changes in survival or body weight relative to Eμ-TCL1 controls. Despite attenuated basal BCR signaling in vivo, R665W conferred resistance to BTK inhibitors and degraders in CLL cell models, suggesting that resistance arises through signaling network rewiring.

Conclusion: These results indicate that PLCγ2 R665W impairs B-cell development and attenuates BCR signaling in vivo, reshaping immune homeostasis and modifying leukemic B-cell expansion without changing the B-cell receptor repertoire. Mb1-Cre+ PLCγ2 R665W mice crossed to the Eμ-TCL1 model still develop CLL but with a trend towards attenuation. This model provides a versatile platform for dissecting how PLCγ2-driven immune alterations influence resistance to targeted therapy and antitumor immunity.

Vindhya Nawaratne, PhD: No relevant conflicts of interest to declare.